Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/17/2018 |
| Start Date: | April 2008 |
| End Date: | January 2011 |
Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes
Patients with diabetes treated with insulin often gain weight, which may deter patients from
adhering to insulin treatment. Detemir is one type of long acting insulin approved by the
Food and Drug Administration for use in people with diabetes. It is similar to other long
acting insulins (Neutral Protein Hagedorn [NPH], glargine) except that it has been associated
with less weight gain compared to other types of insulin. The reasons for this are still
unclear. One possibility is that detemir insulin acts differently than do other insulins in
affecting how diabetic patients eat meals. The purpose of this study is to determine whether
appetite and calories eaten during a meal are affected by the type of insulin used to treat
diabetes. This is a pilot study which means we are gathering preliminary information to
determine if a larger study can be done.
adhering to insulin treatment. Detemir is one type of long acting insulin approved by the
Food and Drug Administration for use in people with diabetes. It is similar to other long
acting insulins (Neutral Protein Hagedorn [NPH], glargine) except that it has been associated
with less weight gain compared to other types of insulin. The reasons for this are still
unclear. One possibility is that detemir insulin acts differently than do other insulins in
affecting how diabetic patients eat meals. The purpose of this study is to determine whether
appetite and calories eaten during a meal are affected by the type of insulin used to treat
diabetes. This is a pilot study which means we are gathering preliminary information to
determine if a larger study can be done.
Insulin detemir is a neutral, soluble long acting insulin analog with weight neutral
properties. In limited studies, it has been shown to result in less weight gain in type 1 and
type 2 diabetics compared with other long acting insulin formations. A possible mechanism for
its weight neutrality is the fatty acid chain that may allow for improved central nervous
system activity and effects on satiety. The primary objective of this study is to determine
if patients with type 1 diabetes consume fewer calories when allowed to eat to satiety while
treated with insulin detemir compared to insulin glargine. Secondary objectives are 1)
subject responses on validated satiety scales and food diaries, 2) bioelectrical impedance
analysis, 3) resting energy expenditure on indirect calorimetry/metabolic cart measurement,
and 4) centrally acting mediators of satiety measured in the serum (Peptide YY [PYY],
ghrelin, leptin).
properties. In limited studies, it has been shown to result in less weight gain in type 1 and
type 2 diabetics compared with other long acting insulin formations. A possible mechanism for
its weight neutrality is the fatty acid chain that may allow for improved central nervous
system activity and effects on satiety. The primary objective of this study is to determine
if patients with type 1 diabetes consume fewer calories when allowed to eat to satiety while
treated with insulin detemir compared to insulin glargine. Secondary objectives are 1)
subject responses on validated satiety scales and food diaries, 2) bioelectrical impedance
analysis, 3) resting energy expenditure on indirect calorimetry/metabolic cart measurement,
and 4) centrally acting mediators of satiety measured in the serum (Peptide YY [PYY],
ghrelin, leptin).
Inclusion Criteria:
- Type 1 diabetes
- Treated with long-acting and meal time insulin therapy for at least 2 years
- Ages 18 to 60 years of age
- Glycosylated hemoglobin value between 7 - 9 mg/dL
- C-peptide value less than 1.0 pmol/ml 90 minutes after oral Boost Plus administration.
Exclusion Criteria:
- Advanced complications of diabetes (nephropathy, retinopathy, significant neuropathy,
coronary artery disease)
- Severe medical illness or medical conditions including congestive heart failure,
angina, liver failure or renal failure
- Pregnancy
- Alcohol or drug abuse or dependence within three months of study entry
- Less than 50 % agreement on 50-item Food Questionnaire with the Food Array "buffet
style" study meal.
- Women of child-bearing age not adhering to the following contraceptive methods: oral
contraceptives, barrier methods including condoms or diaphragm, or abstinence.
We found this trial at
1
site
Click here to add this to my saved trials
